El Foro de El Anzuelo Club de Pesca
[
Inicio
] [
Nuevo Tema
]
Autor
Titulo
Mensaje
[citar]Best Site good looking http://tiava.in.net/ tiava com According to Bayer, it has also made good progress in the development of new treatment options for patients with gynecological diseases. sPRM (BAY 1002670), a novel oral progesterone receptor modulator, holds the promises of long-term treatment of patients with symptomatic uterine fibroids. Based on promising early clinical data, the initiation of a Phase III study is planned for the middle of 2014. [/citar]